Mylotarg (Gemtuzumab Ozogamicin)

Gemtuzumab ozogamicin, the active ingredient in Mylotarg, is a antibody‑drug conjugate presented as a lyophilized powder for solution for infusion for intravenous use. It treats CD33‑positive acute myeloid leukemia in combination with chemotherapy.

GNH USA supplies Mylotarg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mylotarg is an antibody‑drug conjugate indicated for CD33‑positive acute myeloid leukemia, acting as part of combination chemotherapy regimens. - Acute Myeloid Leukemia (CD33‑positive): Used with chemotherapy to improve remission rates. - Newly diagnosed AML (CD33‑positive): Added to standard induction therapy to increase overall survival. - Relapsed or refractory AML (CD33‑positive): Provides an additional option when standard therapies have failed.

Mylotarg may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Fever and chills: transient pyrexia often related to infusion reactions. - Fatigue: generalized tiredness reported by many patients. - Infusion‑related reactions: flushing, rash, or mild hypotension during administration.

Serious or Rare Side Effects: - Veno‑occlusive disease of the liver: potentially life‑threatening hepatic toxicity. - Severe infections: increased susceptibility due to myelosuppression. - Hemorrhage: bleeding events linked to thrombocytopenia or coagulopathy.

Before initiating therapy with Mylotarg, clinicians should consider several safety measures. - Monitor liver function: baseline and periodic tests are required due to risk of hepatotoxicity. - Assess for veno‑occlusive disease: watch for abdominal pain, weight gain, and jaundice. - Avoid concomitant hepatotoxic drugs: reduce the potential for liver injury. - Pregnancy: use is not recommended; safety data are lacking. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mylotarg can interact with other medicines, necessitating careful management.

Major Interactions (Avoid): - Concomitant hepatotoxic agents: may amplify liver toxicity. - Strong CYP3A4 inducers: could lower the effectiveness of the calicheamicin payload. - Other CD33‑targeted therapies: overlapping toxicities increase risk.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk. - Live vaccines: immunosuppression may reduce vaccine efficacy. - Additional myelosuppressive chemotherapy: may exacerbate cytopenias.